Marianne Helenius
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marianne Helenius has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Kjeld Schmiegelow
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark
3 shared publications - Ramneek Gupta
Novo Nordisk, Oxford, United Kingdom
3 shared publications - Rikke Linnemann Nielsen
Novo Nordisk Research Centre Oxford, Oxford, UK
3 shared publications - Arja Harila-Saari
Department of Women's and Children's Health Uppsala University Uppsala Sweden
2 shared publications Hanne Vibeke Marquart
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
2 shared publications- Liv Andrés-Jensen
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark
2 shared publications
Latest Publications
- 4 November 2026
- Published by Wiley in Pediatric Blood & Cancer
Germline ATP2B2 Variant Associates With Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia
Background: Genome‐wide association studies (GWASs) can uncover inherited determinants of clinically relevant leukemia phenotypes, but their utility depends on precise phenotyping. Central nervous system (CNS) involvement in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is prognostically important, but its underlying biology remains poorly understood. We investigated inherited determinants using a sensitive, standardized definition of CNS involvement. Procedure: We conducted a pooled observational cohort GWAS of CNS involvement at diagnosis among 674 patients with BCP‐ALL from the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 and ALLTogether1 cohorts. CNS involvement was defined as ≥10 leukemic blasts detected in diagnostic cerebrospinal fluid by flow cytometry (FCM). Association testing used logistic regression adjusted for white blood cell count and genetic ancestry. Cox regression assessed variant associations with time to relapse. Findings were evaluated in an independent Associazione Italiana di Ematologia e Oncologia Pediatrica–Berlin–Frankfurt–Münster ALL 2000 protocol (AIEOP‐BFM2000) cohort through targeted analysis. Results: Among 10,242,929 variants passing quality control, rs13059398, an intronic ATP2B2 variant, was associated with CNS involvement at genome‐wide significance ( p = 3.28 × 10 −8 ; odds ratio [OR] = 6.07; 95% confidence interval, 3.2–11.5). The variant was carried by 21/113 (18.6%) CNS‐positive and 29/559 (5.2%) CNS‐negative patients. Although directionally consistent in the validation cohort, the association was not statistically significant. ATP2B2 , predominantly expressed in CNS tissues, encodes the plasma membrane Ca 2+ ATPase plasma membrane calcium ATPase 2 (PMCA2). There was no association with time to relapse. Conclusions: Germline variation at ATP2B2 was associated with FCM‐defined CNS involvement in childhood BCP‐ALL. These findings identify ATP2B2 as a candidate locus for further investigation of the biological mechanisms underlying leukemic CNS involvement.
- 4 November 2026
- Published by Wiley in Pediatric Blood & Cancer
Germline ATP2B2 Variant Associates With Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia
Background: Genome‐wide association studies (GWASs) can uncover inherited determinants of clinically relevant leukemia phenotypes, but their utility depends on precise phenotyping. Central nervous system (CNS) involvement in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is prognostically important, but its underlying biology remains poorly understood. We investigated inherited determinants using a sensitive, standardized definition of CNS involvement. Procedure: We conducted a pooled observational cohort GWAS of CNS involvement at diagnosis among 674 patients with BCP‐ALL from the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 and ALLTogether1 cohorts. CNS involvement was defined as ≥10 leukemic blasts detected in diagnostic cerebrospinal fluid by flow cytometry (FCM). Association testing used logistic regression adjusted for white blood cell count and genetic ancestry. Cox regression assessed variant associations with time to relapse. Findings were evaluated in an independent Associazione Italiana di Ematologia e Oncologia Pediatrica–Berlin–Frankfurt–Münster ALL 2000 protocol (AIEOP‐BFM2000) cohort through targeted analysis. Results: Among 10,242,929 variants passing quality control, rs13059398, an intronic ATP2B2 variant, was associated with CNS involvement at genome‐wide significance ( p = 3.28 × 10 −8 ; odds ratio [OR] = 6.07; 95% confidence interval, 3.2–11.5). The variant was carried by 21/113 (18.6%) CNS‐positive and 29/559 (5.2%) CNS‐negative patients. Although directionally consistent in the validation cohort, the association was not statistically significant. ATP2B2 , predominantly expressed in CNS tissues, encodes the plasma membrane Ca 2+ ATPase plasma membrane calcium ATPase 2 (PMCA2). There was no association with time to relapse. Conclusions: Germline variation at ATP2B2 was associated with FCM‐defined CNS involvement in childhood BCP‐ALL. These findings identify ATP2B2 as a candidate locus for further investigation of the biological mechanisms underlying leukemic CNS involvement.
- Open Access
- 8 December 2025
- Published by Springer Nature in Leukemia
- Vol. 40 (1) , 3-24
Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia
Childhood acute lymphoblastic leukemia (ALL) is a genetically heterogeneous disease, and while somatic alterations inform diagnosis and treatment stratification, germline variants - particularly common host genome variants - rarely influence clinical care. Over the past decade, various host genome variant studies have uncovered numerous common variants associated with ALL susceptibility, treatment efficacy, and toxicity risk. Yet, less than a handful have reached clinical implementation, with TPMT and NUDT15 variants being the only ones widely used clinically. Whether a variant can be readily translated into the clinical setting primarily depends on four features: (1) Phenotype severity, (2) phenotype rarity and the proportion of cases (overall or in subsets of patients) accounted for by genetic variants, (3) the application of the variant as an add-on clinical decision support tool, and (4) the availability, cost, and potential side effects of interventions and/or prophylaxis. Key barriers for such clinical translation include insufficient effect sizes, lack of replication across diverse populations, and lack of well-established treatment modification strategies. However, large-scale international collaborations can generate the necessary statistical power, including enabling more complex bioinformatic approaches, such as polygenic risk scores and more advanced machine learning strategies. In this review, we outline the necessary steps toward bridging the gap between genetic discovery and clinical practice.
- 8 December 2025
- Published by Springer Nature in Leukemia
- Vol. 40 (1) , 3-24
Open AccessRole of common host genome variants in Childhood Acute Lymphoblastic Leukemia
Childhood acute lymphoblastic leukemia (ALL) is a genetically heterogeneous disease, and while somatic alterations inform diagnosis and treatment stratification, germline variants - particularly common host genome variants - rarely influence clinical care. Over the past decade, various host genome variant studies have uncovered numerous common variants associated with ALL susceptibility, treatment efficacy, and toxicity risk. Yet, less than a handful have reached clinical implementation, with TPMT and NUDT15 variants being the only ones widely used clinically. Whether a variant can be readily translated into the clinical setting primarily depends on four features: (1) Phenotype severity, (2) phenotype rarity and the proportion of cases (overall or in subsets of patients) accounted for by genetic variants, (3) the application of the variant as an add-on clinical decision support tool, and (4) the availability, cost, and potential side effects of interventions and/or prophylaxis. Key barriers for such clinical translation include insufficient effect sizes, lack of replication across diverse populations, and lack of well-established treatment modification strategies. However, large-scale international collaborations can generate the necessary statistical power, including enabling more complex bioinformatic approaches, such as polygenic risk scores and more advanced machine learning strategies. In this review, we outline the necessary steps toward bridging the gap between genetic discovery and clinical practice.
- Top Cited PapersOpen Access
- 1 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Data-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using interpretable machine learning
Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients’ lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA diagnosis, integrating retrospective clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC: 0.72, 95%CI (0.71–0.73)). Higher age, BMI and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction ahead of diagnosis. We identified 14 subgroups of OA risk profiles. These subgroups were validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients being uniquely assigned to one of the 14 subgroups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g., GDF5 and TGF-β signalling) and OA-specific biomarkers (e.g., CRTAC1 and COL9A1). In summary, this work identifies opportunities for personalised OA prevention and insights into its underlying pathogenesis.
- 1 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Top Cited PapersOpen AccessData-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using interpretable machine learning
Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients’ lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA diagnosis, integrating retrospective clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC: 0.72, 95%CI (0.71–0.73)). Higher age, BMI and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction ahead of diagnosis. We identified 14 subgroups of OA risk profiles. These subgroups were validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients being uniquely assigned to one of the 14 subgroups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g., GDF5 and TGF-β signalling) and OA-specific biomarkers (e.g., CRTAC1 and COL9A1). In summary, this work identifies opportunities for personalised OA prevention and insights into its underlying pathogenesis.
- Open Access
- 10 August 2023
- Published by Springer Nature in Research Square
Data-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using an interpretable machine learning framework: a UK biobank study
Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients’ lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA, integrating clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC:0.72 95%CI (0.71 – 0.73)). Higher age, BMI, and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction. 14 sub-groups of OA risk profiles were identified, and validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients uniquely assigned to one of the sub-groups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g. GDF5 and TGF-β signalling) and identified OA-specific biomarkers (e.g. CRTAC1 and COL9A1). In summary, this work identified opportunities for personalised OA prevention and insights into its underlying pathogenesis.
- 10 August 2023
- Published by Springer Nature in Research Square
Open AccessData-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using an interpretable machine learning framework: a UK biobank study
Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients’ lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA, integrating clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC:0.72 95%CI (0.71 – 0.73)). Higher age, BMI, and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction. 14 sub-groups of OA risk profiles were identified, and validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients uniquely assigned to one of the sub-groups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g. GDF5 and TGF-β signalling) and identified OA-specific biomarkers (e.g. CRTAC1 and COL9A1). In summary, this work identified opportunities for personalised OA prevention and insights into its underlying pathogenesis.
- Open Access
- 22 March 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (6) , e29582
Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype–genotype study
Background: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well‐known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of host genome variants, is poorly understood.Methods: We included patients treated with the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL‐2008 protocol (N = 2347, 72% were genotyped by Illumina Omni2.5exome‐8‐Bead chip) aged 1–45 years, diagnosed with B‐cell precursor (BCP‐) or T‐cell ALL (T‐ALL) to investigate the variation in WBC. Spline functions of WBC were fitted correcting for association with age across ALL subgroups of immunophenotypes and karyotypes. The residuals between spline WBC and actual WBC were used to identify WBC‐associated germline genetic variants in a genome‐wide association study (GWAS) while adjusting for age and ALL subtype associations.Results: We observed an overall inverse correlation between age and WBC, which was stronger for the selected patient subgroups of immunophenotype and karyotypes (ρBCP‐ALL = −.17, ρT‐ALL = −.19; p < 3 × 10−4). Spline functions fitted to age, immunophenotype, and karyotype explained WBC variation better than age alone (ρ = .43, p << 2 × 10−6). However, when the spline‐adjusted WBC residuals were used as phenotype, no GWAS significant associations were found. Based on available annotation, the top 50 genetic variants suggested effects on signal transduction, translation initiation, cell development, and proliferation.Conclusion: These results indicate that host genome variants do not strongly influence WBC across ALL subsets, and future studies of why some patients are more prone to hyperleukocytosis should be performed within specific ALL subsets that apply more complex analyses to capture potential germline variant interactions and impact on WBC.
- 22 March 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (6) , e29582
Open AccessCharacteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype–genotype study
Background: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well‐known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of host genome variants, is poorly understood.Methods: We included patients treated with the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL‐2008 protocol (N = 2347, 72% were genotyped by Illumina Omni2.5exome‐8‐Bead chip) aged 1–45 years, diagnosed with B‐cell precursor (BCP‐) or T‐cell ALL (T‐ALL) to investigate the variation in WBC. Spline functions of WBC were fitted correcting for association with age across ALL subgroups of immunophenotypes and karyotypes. The residuals between spline WBC and actual WBC were used to identify WBC‐associated germline genetic variants in a genome‐wide association study (GWAS) while adjusting for age and ALL subtype associations.Results: We observed an overall inverse correlation between age and WBC, which was stronger for the selected patient subgroups of immunophenotype and karyotypes (ρBCP‐ALL = −.17, ρT‐ALL = −.19; p < 3 × 10−4). Spline functions fitted to age, immunophenotype, and karyotype explained WBC variation better than age alone (ρ = .43, p << 2 × 10−6). However, when the spline‐adjusted WBC residuals were used as phenotype, no GWAS significant associations were found. Based on available annotation, the top 50 genetic variants suggested effects on signal transduction, translation initiation, cell development, and proliferation.Conclusion: These results indicate that host genome variants do not strongly influence WBC across ALL subsets, and future studies of why some patients are more prone to hyperleukocytosis should be performed within specific ALL subsets that apply more complex analyses to capture potential germline variant interactions and impact on WBC.